Logo image
Sign in
Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
Journal article

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Leslie M. Randall, Michael W. Sill, Robert A. Burger, Bradley J. Monk, Barbara Buening and Joel I. Sorosky
Gynecologic Oncology, Vol.124(3), pp.563-568
2012
PMID: 22138229

Metrics

5 Record Views

Details